Compare KNRX & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KNRX | ELUT |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.6M | 48.3M |
| IPO Year | N/A | 2020 |
| Metric | KNRX | ELUT |
|---|---|---|
| Price | $1.26 | $1.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 58.7K | ★ 75.2K |
| Earning Date | 06-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 146.77 |
| EPS | N/A | ★ 0.87 |
| Revenue | N/A | ★ $12,293,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.83 |
| P/E Ratio | ★ N/A | $1.32 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.76 | $0.50 |
| 52 Week High | $3.45 | $2.60 |
| Indicator | KNRX | ELUT |
|---|---|---|
| Relative Strength Index (RSI) | 42.89 | 50.60 |
| Support Level | $0.83 | $1.00 |
| Resistance Level | $1.45 | $1.16 |
| Average True Range (ATR) | 0.20 | 0.07 |
| MACD | -0.05 | -0.00 |
| Stochastic Oscillator | 14.81 | 61.11 |
Knorex Ltd is a B2B technology company providing programmatic advertising products and solutions to marketers to streamline and automate their advertising and marketing workflows. Its software offers marketers cost-effective solutions and productivity-enhancing capabilities to target audience across various advertising channels and devices through automated processes and algorithms, which is known as programmatic advertising. Its product, Knorex XPOSM, is a self-service enterprise-grade cloud platform with a suite of advertising management and execution (AMX) applications. The Company operates in one operating segment, which focuses on platform subscription fee, platform services, managed activations, and professional services.
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.